Phase 2 Study in Systemic Lupus Erythematosus (SLE)

Double-blind, randomized, placebo-controlled study

Primary Endpoint: Musculoskeletal Pain assessed by NRS-Pain Score

Secondary Endpoints: Overall disease activity using SLE Responder Index; Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA); SLE Disease Activity Index (SLEDAI); British Isles Lupus Activity Group (BILAG)

Key study inclusion criteria:*

  • Fulfill updated ACR 1997 Revised Criteria for the Classification of Systemic Lupus Erythematous
  • 18 years of age and less than 70 at the time consent is signed
  • Seven-day average of maximum of daily pain NRS scores ≥4 out of 10 during screening with continued reporting of pain NRS scores on at least 67% of days during the screening period.

*There are additional criteria you must meet to be able to participate in this study.

For Complete Study Details, Please View the Study Listing on Identifier: NCT03093402

Medical professionals may email us at for more information about study participation.

Patients, caregivers or patient advocates looking for additional information may email us at

For any other inquiries, please see our Contact Us page.